I remember in the last
recession hearing a PR adviser saying that they were telling their corporate
clients not to listen to the news and comment programmes before going into
work. It was challenging enough to motivate yourself and your colleagues in a
difficult environment without being dragged down by relentless bad news and
aggressive interviews.
Although I did listen to the
news before work I avoided programmes like the Today programme except in small bites because I found the style of
interviewing too aggressive for that time of the morning. I haven’t really
changed my view. The other thing that
really annoys me is that the presenters seem to think that we are more
interested in hearing them than the interviewee and constantly interrupt and
paraphrase. I admit I don’t listen very often so perhaps I have just been
unfortunate in the bits I have heard.
However on December 10
I was pleased I was listening, as there was an interview with Professor Randy
Schekman due to be presented with his Nobel prize* for medicine on that day and
the Deputy Editor of Science, Andrew
Sugden. Schekman was criticising the three leading scientific journals – Science, Cell and Nature.
I quote from his
article in the Guardian - How
journals like Nature, Cell and Science are damaging science. The sub
headline was incentives offered by top
journals distort science just as big bonuses distort banking. I can’t make up my mind whether that
statement is a good comparison or not – but it makes a good headline! He writes:
“I am a scientist. Mine is a
professional world that achieves great things for humanity. But it is disfigured
by inappropriate incentives ...... We all know what distorting incentives have
done to finance and banking. The incentives my colleagues face are not huge
bonuses, but the professional rewards that accompany publication in prestigious
journals – chiefly Nature, Cell and Science.”
He is, of course, correct in that
publication in a prestigious journal can substantially enhance a scientist’s
career and bring glory to their institution. But, these are predominantly print
journals and this brings an artificial limitation to the number of excellent
research papers that can be published. This not only delays publication
unnecessarily (which in itself slows down research) but also excludes good
research for reasons of space rather than quality.
Schekman is an advocate of open access
journals as am I. This ensures that
research is available to the widest audience anywhere in the world but it must
be thoroughly peer-reviewed and only sound research must be published. It is difficult to argue with that and
although Sugden said that Science is
now publishing additional articles on-line – I think the days of the
subscription only print journal are numbered.
Schekman is Editor-in-chief of eLife
where working scientists assess and select papers for publication, and all
science judged to be of the calibre and high standard that eLife
requires is published in the journal; there are no print-based limitations.
And, all content published in eLife is openly available for all to use
and re-use for free. The journal is backed by the Howard Hughes Medical
Institute, the Max Planck Society, and the Wellcome Trust – a very prestigious
group of institutions.
When Breast Cancer Campaign commissioned
its first ground-breaking Gap Analysis the resulting paper was published in
2008 in the on-line, open access journal Breast
Cancer Research (and subsequently accessed over 40,000 times). The second Gap Analysis was
published recently in the same journal and has also been ‘highly
accessed’. I think that rather proves
the point.
* Randy Schekman, Thomas C Südhof and
James were awarded the 2013 Nobel Prize for Physiology or Medicine "for
their discoveries of machinery regulating vesicle traffic, a major transport
system in our cells"
No comments:
Post a Comment